• By Concept
  • By Last Name
  • By Full Text

Mufson, Elliott J

Grant Detail

The grant detail shows the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the fingerprint of the grant. If any publications referencing this grant are found in the data, they will be listed here as well.



ALZHEIMER'S DISEASE COOPERATIVE STUDY

Thal, Leon J

30 September 1991 - 31 August 2006
NATIONAL INSTITUTE ON AGING
Total Funding: $ 101,247,675

FY 2005
5U01AG010483-15
$ 9,139,210
FY 2004
3U01AG010483-14S1
$ 90,000
FY 2004
5U01AG010483-14
$ 12,004,726
FY 2003
5U01AG010483-13
$ 12,123,984
FY 2002
5U01AG010483-12
$ 11,094,321
FY 2002
3U01AG010483-12S1
$ 99,999
FY 2001
2U01AG010483-11
$ 10,105,572
FY 2001
3U01AG010483-10S1
$ 91,000
FY 2000
5U01AG010483-10
$ 5,761,712
FY 1999
5U01AG010483-09
$ 6,656,564
FY 1998
3U01AG010483-08S1
$ 132,466
FY 1998
3U01AG010483-08S2
$ 88,570
FY 1998
5U01AG010483-08
$ 5,850,604
FY 1997
5U01AG010483-07
$ 3,932,656
FY 1997
3U01AG010483-07S1
$ 1,662,501
FY 1996
2U01AG010483-06
$ 4,177,886
FY 1995
5U01AG010483-05
$ 4,116,137
FY 1994
5U01AG010483-04
$ 4,045,264
FY 1993
5U01AG010483-03
$ 3,716,839
FY 1992
5U01AG010483-02
$ 3,677,663
FY 1991
1U01AG010483-01
$ 2,680,001
 
 
$ 101,247,675
Abstract

This proposal is for a five year renewal (years 11 through 15) of the Alzheimer's Disease Cooperative Study (ADCS). This consortium of 34 academic medical centers and 65 participating sites is proposing to continue to carry out clinical drug trials for promising to continue to carry out clinical drug trials for promising new agents designed to ameliorate behavioral symptoms, improve cognition, slow the rate of decline or delay the appearance of Alzheimer's disease (AD). We will also expand our efforts in the recruitment of minority groups into AD clinical trials. Development of instruments will now shift to developing instruments suitable for data collection in primary prevention trials where data can be collected efficiently in a subjects home and returned by mail with minimal use of interviewer time, allowing for cost-effective, large prevention trials. Subjects in our trials will range from normal individuals to individuals with moderate dementia. Trials will range in size from small 1A trials involving 15 subjects to a very large primary prevention trials with a planned enrollment of 2,700 normal elderly. As a follow-up to our previous vitamin E trial and ongoing MCI trial, we are proposing a primary prevention trial to test the theory that the use of cellular and mitochondrial antioxidants, both alone and in combination, will prevent the development of AD in normal elderly. Our new protocols will also include the development of two new molecules (a neuroactive peptide [NAP] and indole-3 propionic acid [IPA], a potential anti-oxidant) that will be tested in Phase 1 trials. We will also test a combination of vitamins (folate/B6/B12) that have been demonstrated to reduce homocysteine levels, a risk factor for AD on the theory that this will lead to a slowing in the rate of decline. A trial of a drug designed to lower cholesterol will follow up on new data suggesting that lower cholesterol decreases the deposition of beta amyloid. We also are including a new trial design employing divalproex sodium to block the emergence of behavioral symptomatology.

143 Resulting Publications

Scientific Context

This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.

Related Grants

Related Publications